Back
Corporate News
Strides Pharma Science’s revenue increased 13% year-over-year to Rs 12,654 million
31-Jul-2026, 01:39
Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) announced its consolidated financial results for the quarter ended June 30, 2026, reporting revenue of Rs 12,654 million, a 13% year-over-year increase, with Ex-US markets growing 17% year-over-year to Rs 5,875 million. The company’s EBITDA rose 5.4% year-over-year to Rs 2,298 million, absorbing a Rs 131 million impact on operating costs due to geopolitical disruptions, while operational profit after tax increased 8% year-over-year to Rs 1,231 million; additionally, Strides unlocked Rs 1,000 million in value through the divestment of its majority stake in Pivot Path, its captive GCC.
Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) announced its consolidated financial results for the quarter ended June 30, 2026, reporting revenue of Rs 12,654 million, a 13% year-over-year increase, with Ex-US markets growing 17% year-over-year to Rs 5,875 million. The company’s EBITDA rose 5.4% year-over-year to Rs 2,298 million, absorbing a Rs 131 million impact on operating costs due to geopolitical disruptions, while operational profit after tax increased 8% year-over-year to Rs 1,231 million; additionally, Strides unlocked Rs 1,000 million in value through the divestment of its majority stake in Pivot Path, its captive GCC.